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Porphyrias are a group of diseases characterized by an enzyme deficiency in the heme biosynthesis pathway, 
resulting in accumulation of precursor molecules in the tissue. Some porphyric patients develop progressive liver 
disease that requires liver transplantation. This case report describes special anesthetic challenges, including careful 
selection of drugs and the use of special filters that can exclude harmful wavelengths of ultraviolet, in a patient with 
porphyria who underwent living donor liver transplantation. Understanding the patient’s status and disease process, 
and avoiding triggering factors of porphyria attacks, are important for successful liver transplantation anesthesia in 
patients with porphyria.  (Korean J Anesthesiol 2012; 62: 83-86)
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Porphyrias are a group of rare diseases related to an enzyme 
deficiency in the heme metabolism. In some cases of porphyria, 
liver transplantation (LT) is considered as the treatment of 
choice for the life-threatening acute attacks resulting in hepatic 
failure. Herein, we report a case of a patient with porphyria who 
underwent LT. 
Case Report
A 23-year-old man (body weight: 60.7 kg, height: 173 cm) 
visited the emergency room with abdominal pain and jaun-
dice, and was admitted for further evaluation. He had been 
diagnosed with biliary cirrhosis 4 years ago, while being 
evaluated with abnormal liver function tests after alcohol 
consumption. Recently, he had visited the emergency room 
twice with abdominal pain, and was discharged after improving 
with conservative management. 
During his workup, hepatosplenomegaly with collateral 
vessels was found on abdominal computed tomography, and 
esophageal varices were found on esophagogastroduodenoscopy. 
His blood test results were, as follows: total bilirubin, 26.1 mg/
dl; direct bilirubin, 16.6 mg/dl; aspartate aminotransferase, 52 
U/L; and alanine aminotransferase, 38 U/L. He had progressing 
proximal limb pain that could not be controlled by opioids. He 
also had skin sensitivity on exposure to sunlight, and there was 
a family history of multiple skin blisters on exposure to sunlight.
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His clinical features were attributed to porphyria, and he 
was found to have increased coproporphyrin in the stool and 
uroporphyrin in the urine. During the workup performed 
to determine the subtype of porphyria, his liver function 
worsened, and he developed acute liver failure. Also, due to the 
hypovolemic shock caused by intra-abdominal bleeding, his 
renal function suddenly deteriorated to the point of needing 
continuous renal replacement therapy. Therefore, on hospital 
day 29, he was listed for an emergency LT.
The preoperative electrocardiogram revealed sinus tachy-
cardia, and his echocardiogram was within normal limits. 
Pulmonary edema and pulmonary effusion were identified 
on his preoperative chest X-ray. According to the preoperative 
laboratory data, his model for end-stage liver disease score was 
33 points. 
He was intubated, and a continuous infusion of norepine-
phrine (0.9 μg/kg/min) was given in the intensive care unit 
(ICU). In the operating room, a Bispectral Index
Ⓡ monitor 
(Aspect Medical Systems. Inc., Norwood, USA) was attached, 
and ventilator care was continued at the same ICU settings.
Arterial cannulation was performed with a 20G catheter 
in the left radial artery, and central venous cannulation was 
performed with a 9-Fr Advanced Venous Access catheter 
(Edwards Lifesciences, Irvine, CA, USA) in the right internal 
jugular vein. A multifunction Swan-Ganz catheter (Edwards 
Lifesciences, Irvine, CA, USA) was inserted for hemodynamic 
monitoring, and the endotracheal tube was changed.
General anesthesia was induced and maintained with total 
intravenous anesthesia, consisting of 2% propofol (100 μg/
kg/min) and remifentanil (0.15 μg/kg/min). The continuous 
infusion of norepinephrine (0.9 μg/kg/min) was maintained. 
The patient had hypovolemic acute renal failure, and atracuro-
nium (5 μg/kg/min) was infused intravenously. The shadowless 
surgical lights were covered with special filters (TA-81 filter 
MAdico Inc., Woburn, USA), and other lights in the operating 
room were turned off before the patient was brought in. 
The LT operation started 75 minutes after induction of 
anesthesia. Dopamine (5 μg/kg/min) was added to maintain 
the mean arterial blood pressure between 60 and 70 mmHg, 
before the anhepatic phase. During the anhepatic period, 
the hemodynamic profile was stable. Immediately before 
the reperfusion, 100% oxygen was given. After reperfusion, 
the mean blood pressure dropped to about 49 mmHg, but it 
was normalized within 2 minutes, without bolus injections of 
inotropics. During the operation, the patient was given 10,200 
ml of crystalloid, 1,500 ml of colloid, 670 ml of 5% albumin, 15 
units of packed red blood cells, 4 units of fresh frozen plasma, 
6 units of platelet concentrate and 6 units of cryoprecipitate. 
Calcium gluconate was given intermittently, based on the 
results of arterial blood gas analyses. He was anuric due to acute 
renal failure; his total urine output was only 100 ml. The patient 
was transferred back to the ICU after 8 hours and 25 minutes of 
surgery. Intraoperative laboratory test results are summarized 
in Table 1.
On the third day after LT, the patient became alert and his 
renal function improved, so the continuous renal replacement 
therapy was discontinued. However, his motor function was 
weak, therefore extubation was delayed.
On the ninth day after LT, his motor power was grade 2, and 
examination revealed that he had severe sensory and motor 
polyneuropathy. He received a tracheostomy on day 13 post-
LT. The patient’s post-LT liver function tests initially improved, 
but worsened again, and were accompanied by fever about 1 
month later. Despite our best efforts to improve his condition, 
including the administration of antibiotics, he developed multi-
organ failure and expired on postoperative day 104.
Discussion
Porphyrias are a group of either inherited or acquired 
enzymatic defects of the heme biosynthesis. According to the 
major site of the abnormal porphyrin production, they are 
Table 1. Perioperative Laboratory Values
Parameter PreOP ICU arrival POD #1 POD #2 POD #3 POD #10
AST/ALT (U/L)
Bilirubin (mg/dl)
Gamma-GT (U/L)
Albumin (g/dl)
BUN (mg/dl)
Creatinine (mg/dl)
Glucose (mg/dl)
PT (INR)
Fibrinogen (mg/dl)
Hemoglobin (g/dl)
9,790/1,169
34.2
66
4.2
26
1.21
106
2.51
184
5.7
1,362/272
6.9
33
2.1
19
1.54
126
2.53
85
9.6
586/235
7.1
-
3.2
32.3
1.74
104
2.68
141
6.5
410/184
7.1
-
3.1
36.4
1.83
154
2.3
167
7.4
321/184
8.4
35
3.4
37.6
1.38
106
1.35
203
8.6
113/118
7.1
-
2.8
63
1.18
144
0.97
179
7.5
AST: aspartate aminotansferase, ALT: alanine aminotransferase, Gamma-GT: gamma-glutamyl transferase, BUN: Blood urea nitrogen, PT: 
prothromnin time, INR: international normalized ratio, PreOP: preoperative, ICU: intensive care uint, POD: postoperative day.85 www.ekja.org
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classified into hepatic and erythropoietic porphyrias. Each type 
of porphyria has a characteristic pattern of overproduction 
and accumulation of heme precursors, based on the location 
of the dysfunctional enzyme in the heme synthesis pathway. 
The hepatic porphyrias include acute intermittent porphyria, 
hereditary coproporphyria, variegate porphyria, aminolevulinic 
acid dehydratase deficiency porphyria and porphyria cutanea 
tarda. The erythropoietic porphyrias include uroporphyria and 
protoporphyria.
Erythropoietic porphyrias are associated with photosensitivity, 
but are not associated with neuropathy or drug-precipitated 
crises. Except for porphyria cutanea tarda, hepatic porphyrias are 
associated with central, peripheral or autonomic neuropathy, 
mental changes, abdominal pain, and crises frequently pre-
cipitated by triggering factors. Infection, dehydration, fever, 
fasting, psychological stress, physiologic hormonal variation, 
excessive alcohol intake and the use of porphyrinogenic drugs, 
such as barbiturates, have been implicated as causes of the 
acute hepatic porphyria crisis. The signs and symptoms of acute 
porphyric crisis are severe abdominal pain, vomiting, anxiety, 
confusion, autonomic instability manifested by hypertension 
and tachycardia, dehydration, and electrolyte disturbances, 
such as hyponatremia, hypokalemia and hypocalcemia. 
The management of acute porphyria includes symptom-
specific treatment for the presenting illness and the use of 
heme arginate, which reduces the aminolevulinic acid synthase 
activity and heme production. Hydration and carbohydrate 
intake may also be considered as supplementary treatment 
options [1].
There were several anesthetic considerations for this 
patient because many anesthetics are metabolized by the P45-
cytochromes and may cause acute attacks of porphyria. From 
this perspective, drugs have been classified as “safe” , “unsafe” , 
or “use with caution” [2]. We chose propofol to induce and 
maintain anesthesia because its safety has been frequently 
reported [3-5]. Furthermore, a case of successful LT for the 
treatment of variegate porphyria was reported, using propofol 
as the anaesthesia induction and maintenance drug [6]. Opioid 
analgesics have been used without problems in porphyric 
patients, and the successful use of remifentanil was recently 
reported [7]. One study identified the porphyrinogenic effects 
of atracuronium [8], but another report indicated that this 
effect was not seen in clinical practice [9]. The vasopressors 
(i.e. dopamine and norepinephrine) administered during the 
operation have not been reported as triggers of acute porphyria 
attacks [10].
Our patient had photosensitivity. In some subtypes of por-
phyria patients undergoing LT, phototoxic injury to abdominal 
organs can cause multiple small bowel perforations, which 
result in uncontrolled sepsis and death [11]. Therefore, we used 
one of the filters recommended for excluding the most harmful 
wavelengths from surgical luminaries. luminaires. Since the 
blue range of the ultraviolet spectrum has been responsible 
for phototoxicity, we covered the shadowless surgical lights 
with filters, and the other lights in the room were turned off, as 
previously reported [12,13]. The cell saver was not used because 
we were unable to find any reports of cell saver use in porphyria 
cases undergoing LT, and the porphyric subtype was not 
confirmed before surgery.
After the LT, the patient’s liver function improved, but the 
neuropathy remained. Neurological disorders in porphyria can 
lead to respiratory paralysis and death. If there is improvement 
in neuropathy, the functional recovery may be complete, 
but tends to take a very long time [14]. Therefore, this patient 
received a tracheostomy.
Gene linkage analysis was planned after ICU discharge in 
order to determine the porphyria subtype, but this analysis was 
not performed because the patient’s condition deteriorated 
after about 1 month. We were unable to confirm his porphyric 
subtype, and presumed that it was variegate porphyria, a 
congenital erythropoietic porphyria, likely responsible for his 
symptoms and some of the test results. 
Postoperative verification of the porphyrin levels in the urine 
is a good indicator of improvement, but it was inconvenient in 
this case, because the test is only carried out twice a month at 
the Red Cross Center in Korea.
This case shows that LT for the treatment of porphyria can be 
performed successfully through close monitoring, minimizing 
perioperative stress, carefully selecting drugs that are safe 
for porphyria patients and effective filters. Although most 
anesthetic agents have been used in porphyria patients without 
problems, caution is necessary.
In conclusion, understanding the patient’s status and the 
disease process and avoiding the triggering factors, based on 
knowledge of the porphyria attacks, are important for successful 
LT anesthesia in porphyria patients. 
References
1. Jensen NF, Fiddler DS, Striepe V. Anesthetic considerations in 
porphyrias. Anesth Analg 1995; 80: 591-9.
2. James MF, Hift RJ. Porphyrias. Br J Anaesth 2000; 85: 143-53.
3. Tidmarsh MD. Porphyria, propofol and rats. Br J Anaesth 1996; 76: 
171-2.
4. Sarantopoulos CD, Bratanow NC, Stowe DF, Kampine JP. Une-
ventful propofol anesthesia in a patient with coexisting here-
ditary coproporphyria and hereditary angioneurotic edema. 
Anesthesiology 2000; 92: 607-9.
5. Asirvatham SJ, Johnson TW, Oberoi MP, Jackman WM. Prolonged 
loss of consciousness and elevated porphyrins following propofol 
administration. Anesthesiology 1998; 89: 1029-31.86 www.ekja.org
Vol. 62, No. 1, January 2012 Anesthesia for porphyric LT
6. Stojeba N, Meyer C, Jeanpierre C, Perrot F, Hirth C, Pottecher T, et 
al. Recovery from a variegate porphyria by a liver transplantation. 
Liver Transpl 2004; 10: 935-8.
7. Durmus M, Turkoz A, Togal T, Koroglu A, Toprak HI, Ersoy MO. 
Remifentanil and acute intermittent porphyria. Eur J Anaesthesiol 
2002; 19: 839-40.
8. Böhrer H, Schmidt H, Bach A, Martin E, Kohl B, Bolsen K, et al. 
Porphyrinogenic effects of atracurium, vecuronium and pancuro-
nium in a primed rat model. Lab Anim Sci 1994; 44: 326-30.
9. Sneyd JR, Kreimer-Birnbaum M, Lust MR, Heflin J. Use of sufentanil 
and atracurium anesthesia in a patient with acute porphyria 
undergoing coronary artery bypass surgery. J Cardiothorac Vasc 
Anesth 1995; 9: 75-8.
10. Moore MR, Hift RJ. Drugs in the acute porphyrias-toxicogenetic 
diseases. Cell Mol Biol (Noisy-le-grand) 1997; 43: 89-94.
11. McGuire BM, Bonkovsky HL, Carithers RL Jr, Chung RT, Goldstein 
LI, Lake JR, et al. Liver transplantation for erythropoietic protopor-
phyria liver disease. Liver Transpl 2005; 11: 1590-6.
12. Asokumar B, Kierney C, James TW, Amato J, Tumanmd KJ. Anaesthetic 
management of a patient with erythropoietic protoporphyria for 
ventricular septal defect closure. Paediatr Anaesth 1999; 9: 356-8.
13. Wahlin S, Srikanthan N, Hamre B, Harper P, Brun A. Protection from 
phototoxic injury during surgery and endoscopy in erythropoietic 
protoporphyria. Liver Transpl 2008; 14: 1340-6.
14. Rigal JC, Blanloeil Y. Anaesthesia and porphyria. Minerva Anestesiol 
2002; 68: 326-31.